Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. STOK
stocks logo

STOK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
5.09M
-77.5%
-0.716
+297.92%
3.88M
-97.55%
-0.775
-140.79%
4.18M
-69.75%
-0.797
+99.37%
Estimates Revision
The market is revising Upward the revenue expectations for Stoke Therapeutics, Inc. (STOK) for FY2025, with the revenue forecasts being adjusted by 1.29% over the past three months. During the same period, the stock price has changed by 50.15%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.29%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-84.78%
In Past 3 Month
Stock Price
Go Up
up Image
+50.15%
In Past 3 Month
Wall Street analysts forecast STOK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STOK is 31.75 USD with a low forecast of 25.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast STOK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STOK is 31.75 USD with a low forecast of 25.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.050
sliders
Low
25.00
Averages
31.75
High
39.00
Current: 31.050
sliders
Low
25.00
Averages
31.75
High
39.00
Canaccord
Buy
maintain
$24 -> $28
2025-11-05
Reason
Canaccord
Price Target
$24 -> $28
2025-11-05
maintain
Buy
Reason
Canaccord raised the firm's price target on Stoke Therapeutics to $28 from $24 and keeps a Buy rating on the shares. The firm said they raised their target on a higher price estimate and 55% probability of approval for zorevunersen in Dravet syndrome with a potential launch in 2028E.
JPMorgan
Neutral
upgrade
$15 -> $25
2025-11-03
Reason
JPMorgan
Price Target
$15 -> $25
2025-11-03
upgrade
Neutral
Reason
JPMorgan raised the firm's price target on Stoke Therapeutics to $25 from $15 and keeps a Neutral rating on the shares ahead of the Q3 report.
BTIG
Thomas Shrader
Buy
maintain
$29 -> $28
2025-08-18
Reason
BTIG
Thomas Shrader
Price Target
$29 -> $28
2025-08-18
maintain
Buy
Reason
BTIG analyst Thomas Shrader lowered the firm's price target on Stoke Therapeutics to $28 from $29 and keeps a Buy rating on the shares. The company's 36-month data for Zorevunersen seems to bury any remaining question, demonstrating seizure reductions deepening in the third year of treatment for patients that started at sub-optimal loading doses and starting and staying impressive for patients that started on the 45 mg loading doses, the analyst tells investors in a research note.
Jefferies
NULL
to
Buy
initiated
$30
2025-07-18
Reason
Jefferies
Price Target
$30
2025-07-18
initiated
NULL
to
Buy
Reason
Jefferies initiated coverage of Stoke Therapeutics with a Buy rating and $30 price target. The firm likes the stock's risk/reward into zorevunersen's Phase III data for Dravet syndrome in the second half of 2027. The trial has a 40%-50% chance of producing differentiated efficacy, potentially opening up a $1B-$1.5B opportunity for Stoke, the analyst tells investors in a research note. Jefferies is looking forward to a potential "material update" from an FDA meeting in the second half of 2025.
H.C. Wainwright
Buy
downgrade
$47 -> $35
2025-05-14
Reason
H.C. Wainwright
Price Target
$47 -> $35
2025-05-14
downgrade
Buy
Reason
Needham
Joseph Stringer
Strong Buy
Reiterates
$22
2025-04-09
Reason
Needham
Joseph Stringer
Price Target
$22
2025-04-09
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Stoke Therapeutics Inc (STOK.O) is -10.03, compared to its 5-year average forward P/E of -7.95. For a more detailed relative valuation and DCF analysis to assess Stoke Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.95
Current PE
-10.03
Overvalued PE
-1.46
Undervalued PE
-14.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.26
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.97
Undervalued EV/EBITDA
-11.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
37.84
Current PS
0.00
Overvalued PS
64.49
Undervalued PS
11.19
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

STOK News & Events

Events Timeline

(ET)
2025-11-17
07:39:02
Stoke Therapeutics and Biogen Release Conclusive Findings from BUTTERFLY Study
select
2025-11-17
07:38:56
Biogen and Stoke Therapeutics Reveal Data from BUTTERFLY Study Publication
select
2025-11-04 (ET)
2025-11-04
16:03:18
Stoke Therapeutics announces Q3 earnings per share of 65 cents, surpassing consensus estimate of 57 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-01Globenewswire
Biogen and Stoke Therapeutics to Present at the 2025 American Epilepsy Society Annual Meeting

  • Zorevunersen Presentation at AES: Biogen and Stoke Therapeutics will present data on zorevunersen, an investigational treatment for Dravet syndrome, at the 2025 American Epilepsy Society Annual Meeting, showcasing four years of clinical data and its potential as a disease-modifying therapy.

  • Clinical Efficacy: The data indicates that zorevunersen may significantly reduce seizure frequency and improve cognitive and behavioral outcomes in patients with Dravet syndrome, with new EEG findings suggesting a correlation between reduced abnormal brain activity and decreased seizure frequency.

  • Ongoing Studies: Zorevunersen is currently being evaluated in the Phase 3 EMPEROR study, which aims to assess its efficacy and safety in children and adolescents with Dravet syndrome, focusing on seizure frequency and overall functioning.

  • Background on Dravet Syndrome: Dravet syndrome is a severe form of epilepsy with no approved disease-modifying therapies, affecting cognitive and behavioral functions, and is often caused by mutations in the SCN1A gene, leading to high seizure rates and associated risks.

[object Object]
Preview
8.0
11-22NASDAQ.COM
Significant Friday Options Trading: HLF, STOK, CRCL

  • Stoke Therapeutics Options Activity: Stoke Therapeutics Inc (STOK) experienced significant options trading with 10,030 contracts, equating to about 1.0 million underlying shares, primarily driven by the $25 strike call option expiring on November 21, 2025.

  • Circle Internet Group Options Activity: Circle Internet Group Inc Class A (CRCL) saw a high volume of 146,016 contracts traded, representing approximately 14.6 million underlying shares, with notable activity in the $80 strike call option expiring on November 28, 2025.

  • Trading Volume Comparison: The options trading volume for STOK accounted for around 90% of its average daily trading volume, while CRCL's options volume represented about 85.8% of its average daily trading volume over the past month.

  • Further Information: For additional details on available expirations for HLF, STOK, or CRCL options, StockOptionsChannel.com can be visited.

[object Object]
Preview
9.0
11-17Globenewswire
Biogen and Stoke Therapeutics Release Two-Year Natural History Data Highlighting the Severity of Dravet Syndrome, Characterized by Frequent Seizures and Notable Cognitive and Behavioral Challenges

  • Dravet Syndrome Impact: Children with Dravet syndrome show a significant plateau in neurodevelopment, remaining at a developmental age of around two years, despite receiving standard anti-seizure treatments, leading to a widening gap compared to typically developing peers.

  • Need for New Treatments: The findings from the BUTTERFLY study highlight the urgent need for new medicines targeting the genetic causes of Dravet syndrome to improve long-term cognitive and behavioral outcomes for affected children.

  • Study Overview: The BUTTERFLY study was a two-year observational study assessing the neurodevelopmental status of children aged 2 to 18 with Dravet syndrome, revealing minimal changes in cognitive and behavioral skills over time.

  • Current Treatment Landscape: There are currently no approved disease-modifying therapies for Dravet syndrome, with over 90% of patients continuing to experience seizures despite the best available treatments.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Stoke Therapeutics Inc (STOK) stock price today?

The current price of STOK is 31.05 USD — it has increased 0.29 % in the last trading day.

arrow icon

What is Stoke Therapeutics Inc (STOK)'s business?

Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

arrow icon

What is the price predicton of STOK Stock?

Wall Street analysts forecast STOK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STOK is 31.75 USD with a low forecast of 25.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Stoke Therapeutics Inc (STOK)'s revenue for the last quarter?

Stoke Therapeutics Inc revenue for the last quarter amounts to 10.63M USD, increased 117.25 % YoY.

arrow icon

What is Stoke Therapeutics Inc (STOK)'s earnings per share (EPS) for the last quarter?

Stoke Therapeutics Inc. EPS for the last quarter amounts to -0.65 USD, increased 38.30 % YoY.

arrow icon

What changes have occurred in the market's expectations for Stoke Therapeutics Inc (STOK)'s fundamentals?

The market is revising Upward the revenue expectations for Stoke Therapeutics, Inc. (STOK) for FY2025, with the revenue forecasts being adjusted by 1.29% over the past three months. During the same period, the stock price has changed by 50.15%.
arrow icon

How many employees does Stoke Therapeutics Inc (STOK). have?

Stoke Therapeutics Inc (STOK) has 128 emplpoyees as of December 05 2025.

arrow icon

What is Stoke Therapeutics Inc (STOK) market cap?

Today STOK has the market capitalization of 1.77B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free